. 2013 Jan 28;31(9):1202–1210. doi: 10.1200/JCO.2012.43.2070

Table 2.

Patient Characteristics and 5-Year EFS Survival Rates of Children and Adolescents With Newly Diagnosed ALL Treated on DFCI ALL Consortium Protocol 00-01 (N = 492)

Characteristic	Total No. of Patients	5-Year EFS (%)	95% CI	P
All evaluable patients	492	80	76 to 84
DFCI risk group				.001
Standard risk	282	85	80 to 89
High risk	210	74	68 to 80
Age, years				.008
1-9.99	380	83	79 to 87
10-18	112	72	63 to 80
Median	4.75
Range	1-17.8
WBC count, ×10⁹/L				.007
< 50,000	391	83	78 to 87
≥ 50,000	101	72	63 to 81
Median	11.4
Range	0.9-865.1
Sex				.04
Male	264	77	71 to 82
Female	228	85	80 to 90
Immunophenotype				.01
B lineage	443	82	78 to 85
T cell	49	69	56 to 82
CNS status at diagnosis				.68
CNS 1	410	80	76 to 84
CNS 2	60	84	74 to 93
CNS 3	17	81	62 to 100
Missing	5
Down syndrome				.34
Yes	13	92	76 to 100
No	479	80	76 to 84
End-induction MRD^*	186			< .0001
Low	168	87	81 to 92
High	18	61	35 to 79
Cytogenetics^†	405
TEL/AML1	98	91	85 to 97
High hyperdiploid	110	88	81 to 95
t(1;19)	14	100
t(9;22)	14	31	6 to 56
MLL rearrangement	14	48	21 to 75

NOTE. Bone marrow cells from diagnostic aspirate samples were examined for cell-surface antigens using direct immunofluorescence assays and were cultured for cytogenetic analyses. Screening for the following translocations by FISH and/or PCR was performed at each participating institution when diagnostic marrow sample was available: TEL/AML1, MLL gene rearrangements, and BCR-ABL.

Abbreviations: ALL, acute lymphoblastic leukemia; DFCI, Dana-Farber Cancer Institute; EFS, event-free survival; FISH, fluorescent in situ hybridization; MRD, minimal residual disease; PCR, polymerase chain reaction.

Includes only B-precursor patients with evaluable MRD results (n = 186).

^†

Includes only patients with evaluable cytogenetic, FISH, and/or PCR results (n = 405).